Clinical Trial Update: Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial updates report results for ranibizumab (Lucentis) in macular edema due to retinal vein occlusion, with completed status as of 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema
• Retinal Vein Occlusion

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Peter A Campochiaro, MD | Conditions: Macular Edema, Retinal Vein Occlusion | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-12-04